Literature DB >> 632356

Crossreaction of antilymphocyte globulin with human granulocyte colony-forming cells.

A J Barrett, P Longhurst, N Rosengurt, J R Hobbs, J G Humble.   

Abstract

Clinical preparations of horse antilymphocyteglobulin (ALG) were found to inhibit human bone marrow granulocyte colony growth. This effect was enhanced by complement and was dose dependent, being almost complete at ALG concentrations of 100 microgram/ml. Inhibition was a property of ALG but not of normal horse globulin. However, short incubation of ALG with bone marrow cells occasionally stimulated colony growth and normal horse globulin regularly stimulated it. Three hours' incubation of bone marrow cells with ALG was needed to produce consistent colony inhibition, which was measurable as a reduction in the expected number of colonies and as a fall in the colony: cluster ratio of surviving cell aggregates. Absorption of ALG on acute myeloid leukaemia blast cells removed the inhibiting property of the ALG while preserving its lymphocytotoxic action. Serum from two patients receiving ALG treatment inhibited colony growth for up to 48 hours after ALG administration. The results suggest the presence in ALG of antibodies specifically cytotoxic to myeloid stem cells which may relate to its myleosuppressive properties in vivo, and also indicate that it should be possible to remove antimyeloid antibodies from ALG by absorption. The use of such purified ALG would have advantages in clinical bone marrow transplantation.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 632356      PMCID: PMC1145202          DOI: 10.1136/jcp.31.2.129

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  11 in total

1.  Bone marrow suppression by antilymphocytic globulin.

Authors:  A J Barrett; J G Humble; J R Hobbs
Journal:  Br Med J       Date:  1975-06-07

2.  Prevention of acute graft-versus-host (GVH) mortality with spleen-absorbed antithymocyte globulin (ATG).

Authors:  J J Trentin; K P Judd
Journal:  Transplant Proc       Date:  1973-03       Impact factor: 1.066

3.  Production of antibodies specific for human thymus derived lymphocytes purified from antibodies crossreacting with colony-forming cells.

Authors:  H Rodt; B Netzel; G Brehm; S Thierfelder
Journal:  Blut       Date:  1974-12

4.  Cytotoxicity for erythroblasts in horse antihuman thymocyte -globulin.

Authors:  S B Krantz
Journal:  Transplantation       Date:  1973-07       Impact factor: 4.939

5.  Treatment of established human graft-versus-host disease by antithymocyte globulin.

Authors:  R Storb; E Gluckman; E D Thomas; C D Buckner; R A Clift; A Fefer; H Glucksberg; T C Graham; F L Johnson; K G Lerner; P E Neiman; H Ochs
Journal:  Blood       Date:  1974-07       Impact factor: 22.113

6.  Human bone marrow colony growth in agar-gel.

Authors:  B L Pike; W A Robinson
Journal:  J Cell Physiol       Date:  1970-08       Impact factor: 6.384

7.  Preparation and characterization of antithymocyte serum and globulin without stem cell activity.

Authors:  B Mosedale; M A Smith; J S Courtenay
Journal:  Transplantation       Date:  1976-08       Impact factor: 4.939

8.  Aplastic anaemia: Evidence for an immunological mechanism.

Authors:  J Ascensão; R Pahwa; W Kagan; J Hansen; M Moore; R Good
Journal:  Lancet       Date:  1976-03-27       Impact factor: 79.321

9.  Brain-associated stem cell antigen: an antigen shared by brain and hemopoietic stem cells.

Authors:  E S Golub
Journal:  J Exp Med       Date:  1972-08-01       Impact factor: 14.307

10.  The effect of heterologous anti-lymphocyte seerum on mouse hemopoietic stem cells.

Authors:  T R DeMeester; N D Anderson; C F Shaffer
Journal:  J Exp Med       Date:  1968-04-01       Impact factor: 14.307

View more
  1 in total

1.  Marrow graft rejection and inhibition of growth in culture by serum in aplastic anaemia.

Authors:  A J Barrett; A Faille; F Saal; N Balitrand; E Gluckman
Journal:  J Clin Pathol       Date:  1978-12       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.